<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies</h2>
    <div class="badge">2025-09-08T10:30:00+00:00</div>
    <ul>
      <li>May 2024.</li>
<li>08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.</li>
<li>Additional Phase 3 development is planned to begin in the first half of 2026.</li>
<li>About 35% of patients continue to experience moderate to severe symptoms despite standard of care therapy.</li>
<li>Itch was reduced by 52% (p&lt;0.0001), conjunctival redness by 39% (p&lt;0.0001) and skin prick reactivity by 44% (p&lt;0.0001).</li>
<li>Itch was reduced by 51% (p&lt;0.0001), conjunctival redness by 46% (p&lt;0.0001), and skin prick reactivity by 44% (p&lt;0.0001).</li>
<li>In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies\n• May 2024.\n• 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.\n• Additional Phase 3 development is planned to begin in the first half of 2026.\n• About 35% of patients continue to experience moderate to severe symptoms despite standard of care therapy.\n• Itch was reduced by 52% (p&lt;0.0001), conjunctival redness by 39% (p&lt;0.0001) and skin prick reactivity by 44% (p&lt;0.0001).\n• Itch was reduced by 51% (p&lt;0.0001), conjunctival redness by 46% (p&lt;0.0001), and skin prick reactivity by 44% (p&lt;0.0001).\n• In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/regeneron-advances-allergy-pipeline-two-103000615.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>